Neuren Pharmaceuticals (ASX:NEU)
ASX announcement history & article coverage
Transparent by design.
Announcments by Neuren Pharmaceuticals (ASX:NEU) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
DAYBU recommended for approval in the European Union
CHMP recommends EU approval for Neuren's DAYBU® to treat Rett syndrome
Application for quotation of securities - NEU
Notification of cessation of securities - NEU
Notification regarding unquoted securities - NEU
Results of Meeting
AGM Chair Address & CEO Presentation
Neuren reports strong 2025 results, advances Phase 3 trial for NNZ-2591, and sees continued growth in DAYBUE royalties
Update - Notification of buy-back - NEU
Launch of Investor Hub to enhance shareholder engagement
Notification of cessation of securities - NEU
Update - Notification of buy-back - NEU
Update - Notification of buy-back - NEU
Q1 2026 DAYBUE net sales US$101m, up 20% from Q1 2025
Neuren Q1 2026 DAYBUE sales up 20%, royalties rise 23%, Japan trial accelerated
Update - Notification of buy-back - NEU
Update - Notification of buy-back - NEU
Virtual AGM online guide
Notice of Annual General Meeting/Proxy Form
Appendix 4G
2025 Annual Report to shareholders
Neuren Pharmaceuticals posts A$30.4m profit in 2025, advances NNZ-2591 Phase 3 trial, initiates share buy-back
Update - Notification of buy-back - NEU
Update - Notification of buy-back - NEU
Update - Notification of buy-back - NEU